Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells 74,764 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 74,764 shares of the stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $0.47, for a total transaction of $35,139.08. Following the transaction, the director now owns 3,840,146 shares in the company, valued at approximately $1,804,868.62. The trade was a 1.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Stock Performance

NASDAQ IVVD traded down $0.01 during trading hours on Thursday, reaching $0.43. The stock had a trading volume of 1,644,881 shares, compared to its average volume of 657,806. Invivyd, Inc. has a 52-week low of $0.43 and a 52-week high of $5.20. The stock has a fifty day moving average of $0.80 and a 200 day moving average of $1.03. The stock has a market cap of $51.40 million, a P/E ratio of -0.22 and a beta of 0.53.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Morgan Stanley reduced their price target on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a research report on Thursday, November 21st. Finally, HC Wainwright reduced their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $7.89.

Institutional Investors Weigh In On Invivyd

Several hedge funds have recently added to or reduced their stakes in IVVD. Proficio Capital Partners LLC acquired a new stake in Invivyd during the third quarter valued at $27,000. SG Americas Securities LLC grew its position in shares of Invivyd by 198.6% during the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock valued at $42,000 after acquiring an additional 25,201 shares during the period. XTX Topco Ltd increased its stake in shares of Invivyd by 68.1% in the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after purchasing an additional 15,376 shares in the last quarter. Cornercap Investment Counsel Inc. acquired a new position in Invivyd in the 2nd quarter worth about $86,000. Finally, Rhumbline Advisers boosted its position in Invivyd by 4,434.1% during the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after purchasing an additional 82,164 shares in the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.